IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA) announced participation in two virtual investor events in February 2026: Citi's Virtual Oncology Leadership Summit on February 18, 2026 at 1:00 PM ET, and IDEAYA's virtual fireside hosted by Evercore on February 23, 2026 at 12:00 PM ET.
Senior executives including the CEO, CMO, CSO, and CFO will appear. Live audio webcasts will be available via the company "Investors/Events" page, with replays accessible for 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IDYA gained 5.81%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.3% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $166M to the company's valuation, bringing the market cap to $3.02B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IDYA was down 2.42% while close peers were mixed: DNLI +1.73%, BLTE +1.42%, FOLD +0.14%, GLPG -0.85%, TVTX -1.52%. No coordinated sector momentum was detected.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Conference participation | Positive | +3.2% | J.P. Morgan Healthcare Conference presentation and webcast details. |
| Dec 11 | Clinical trial update | Positive | -0.2% | Completion of full enrollment in pivotal OptimUM-02 darovasertib trial. |
| Dec 10 | IND submission | Positive | -1.3% | IND submission for IDE574, a KAT6/7 dual inhibitor, to the FDA. |
| Dec 04 | IND clearance | Positive | +4.7% | FDA IND clearance for IDE034 ADC licensed from Biocytogen. |
| Dec 01 | IND clearance | Positive | -3.7% | FDA IND clearance for IDE034, enabling a Phase 1 solid tumor trial. |
Positive pipeline and conference news has produced mixed reactions, with slightly more divergences than alignments.
Over the past few months, IDEAYA has reported multiple clinical and corporate milestones, including IND submissions and clearances for IDE034 and IDE574, and participation in major investor events like the 44th Annual J.P. Morgan Healthcare Conference. Price reactions have varied: some clinically focused releases saw gains up to 4.69%, while others, including positive trial and IND updates, saw modest declines. Today’s announcement of February 2026 investor relations events fits that pattern of frequent outreach to the investment community without adding new clinical or financial data.
Market Pulse Summary
The stock moved +5.8% in the session following this news. A strong positive reaction aligns with IDEAYA’s ongoing efforts to maintain high visibility with investors, including prior events like the January 2026 J.P. Morgan conference. Historically, conference and IND-related news produced mixed but sometimes sizeable moves, with reactions up to about 4–5%. A larger upside response to these February investor events could reflect renewed interest in the broader pipeline and 2026 objectives outlined in recent 8-K filings, but past divergences highlight that enthusiasm can fade if subsequent clinical or corporate updates disappoint.
AI-generated analysis. Not financial advice.
Citi's 2026 Virtual Oncology Leadership Summit
Wednesday, February 18th, 2026 at 1:00 PM ET
- Fireside chat with Darrin Beaupre, Chief Medical Officer; Michael White, Chief Scientific Officer; and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
IDEAYA Biosciences' Virtual Fireside Chat hosted by Umer Raffat of Evercore ISI
Monday, February 23rd, 2026 at 12:00 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer; Darrin Beaupre, Chief Medical Officer; Michael White, Chief Scientific Officer; and Joshua Bleharski, Chief Financial Officer, hosted by Umer Raffat, Senior Managing Director, Biotech and Pharma Equity Research.
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-february-2026-investor-relations-events-302675666.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When will IDEAYA (IDYA) present at Citi's 2026 Virtual Oncology Leadership Summit?
Who will speak for IDEAYA (IDYA) at the February 23, 2026 Evercore virtual fireside?
How can investors access IDEAYA's (IDYA) live audio webcasts for the February 2026 events?
Will IDEAYA (IDYA) provide a replay of the February 2026 investor event webcasts?
What topics are expected at IDEAYA's (IDYA) February 2026 fireside chats?
